"Lung function and onset of cardiometabolic diseases in the longitudina" by Christer Janson, James Potts et al.
 

Lung function and onset of cardiometabolic diseases in the longitudinal burden of obstructive lung disease study

Authors

Christer Janson, Uppsala Universitet, Uppsala, Sweden
James Potts, Imperial College London, London, UK
Andrei Malinovschi, Uppsala University, Uppsala, Sweden
Dhiraj Agarwal, KEM Hospital Pune Research Centre, Pune, Maharashtra, India
Rana Ahmed, The Epidemiological Laboratory, Khartoum, Sudan
Althea Aquart- Stewart, The University of the West Indies, Kingston, Jamaica
Imed Harrabi, Faculté de Médecine, Sousse, Tunisia
Meriam Denguezli, Universite de Sousse Faculte de Medecine de Sousse, Sousse, Tunisia
Graham Devereux, Liverpool School of Tropical Medicine, Liverpool, UK
Gregory E. Erhabor, Obafemi Awolowo University, Ife, Nigeria
Thorarinn Gislason, Landspitali University Hospital, Reykjavik, Iceland
Rain Jogi, Tartu University Hospital, Tartu, Estonia
Sanjay K. Juvekar, Independent Consultant, Pune, Maharashtra, India
Ben Knox- Brown, Imperial College London, London, UK
Parvaiz Koul, ulmonary Medicine, SKIMS, Srinagar, India
Kevin Mortimer, University of Cambridge, Cambridge, UK
Asaad Ahmed Nafees, Aga Khan UniversityFollow
Rune Nielsen, University of Bergen, Bergen, Norway
Padukudru Anand Mahesh, JSS Medical College and Hospital, Mysore, Karnataka, India
Stefanni Nonna M Paraguas, Philippine College of Chest Physicians, Manila, Philippines
Anders Ørskov Rotevatn, Haukeland University Hospital, Bergen, Norway
Talant Sooronbaev, National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Peter G J Burney, Imperial College London, London, UK
Andre F S Amaral, Imperial College London, London, UK

Document Type

Article

Department

Community Health Sciences

Abstract

Introduction: Previous population-based studies, mainly from high-income countries, have shown that a higher forced vital capacity (FVC) is associated with a lower risk of developing cardiometabolic diseases. The aim of this study was to assess the longitudinal association between spirometry measures and the onset of cardiometabolic diseases across sites in low-income, middle-income and high-income countries.
Methods: The study population comprised 5916 individuals from 15 countries participating in the Burden of Obstructive Lung Disease baseline and follow-up assessments. Postbronchodilator forced expiratory volume in 1 s (FEV1), FVC and FEV1/FVC were measured at baseline. Participants who reported having doctor-diagnosed hypertension, diabetes, heart disease and stroke at follow-up but not at baseline were considered new cases of these diseases. The association between lung function and the onset of participant-reported cardiometabolic diseases was assessed in each site using regression models, and estimates were combined using random effects meta-analysis. Models were adjusted for sex, age, smoking, body mass index and educational level.
Results: Participants with greater per cent predicted FVC were less likely to have new-onset diabetes (OR per 10%=0.91, 95% CI 0.84 to 0.99), heart disease (OR per 10%=0.86, 95% CI 0.80 to 0.92) and stroke (OR per 10%=0.81, 95% CI 0.73 to 0.89) during the follow-up period (mean±SD 9.5±3.6 years). A greater percentage of FEV1 was associated with a lower risk of onset of heart disease and stroke. No significant association was found between FEV1/FVC and onset of reported cardiometabolic diseases, except for a higher risk of diabetes (OR per 10%=1.21, 95% CI 1.08 to 1.35) in participants with higher FEV1/FVC.
Conclusions: The findings of this study suggest that a low FVC is more important than a low FEV1/FVC as a risk factor for developing cardiometabolic diseases. The value of including FVC in risk score models to improve their precision in predicting the onset of cardiometabolic diseases should be explored.

Publication (Name of Journal)

BMJ Open Respiratory Research

DOI

10.1136/bmjresp-2024-002442

Share

COinS